ABSTRACT
Background: Severe covid-19 disease has led to many death. Some post mortem study has investigated the cause. The autopsy revealed occurrence of DVT and postmortem lung CT showed reticular infiltration, dense consolidation, while histologically showed diffuse alveolar damage. Through FOB conducted In mechanically ventilated COVID-19 patient, airway obstruction was seen due to hypersecretion and mucus plug in the bronchi. Inhaled budesonide in COVID-19 patient has showed faster recovery and the research focus in the administration of ICS is limited. Objective(s): This study aims to investigate the benefit of LABACS treatment in LONG COVID-19 patients in Pringsewu Indonesia. Method(s): The method of this research was cross sectional. Total subjects included in this study were 276 patients. 168 subjects were treated with Beclomethasone-Formoterol (61%), 49 subjects were treated with FluticasoneSalmeterol (17%), 59 subjects were treated with Budesonide-Formoterol (22%) during 3 months period. We assessed symptoms improvement, mMRC score and chest X-ray imaging. Spirometry of 34 subjects were measured. Result(s): There was a significant correlation between the incidence of lung obstruction and persistent symptom of long covid patients according to spirometry measurement (P value = 0.000). There was a significant correlation between symptoms improvement, mMRC score and chest X-ray imaging after treatment with Beclomethasoneformoterol (p-value = <0.05) Fluticasone-Salmeterol (P value = <0.05) Budesonide-Formoterol (P value = 0.002, P value = 0.007, P value = 0.049). Conclusion(s): LABACS treatment improved lung function and clinically benefit in managing obstruction due to COVID-19.